SEARCH

SEARCH BY CITATION

REFERENCES

  • Afonja O, Smith JE, Jr., Cheng DM, Goldenberg AS, Amorosi E, Shimamoto T, Nakamura S, Ohyashiki K, Ohyashiki J, Toyama K, Takeshita K. 2000. MEIS1 and HOXA7 genes in human acute myeloid leukemia. Leuk Res 24:849855.
  • Allander SV, Ehrenborg E, Luthman H, Powell DR. 1995. Conservation of IGFBP structure during evolution: cloning of chicken insulin-like growth factor binding protein-5. Prog Growth Factor Res 6:159165.
  • Argiropoulos B, Humphries RK. 2007. Hox genes in hematopoiesis and leukemogenesis. Oncogene 26:67666776.
  • Bach C, Buhl S, Mueller D, Garcia-Cuellar MP, Maethner E, Slany RK. 2010. Leukemogenic transformation by HOXA cluster genes. Blood 115:29102918.
  • Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, Candinas D, Greiner RH, Lipson KE, Zimmer Y. 2004. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23:53875393.
  • Bikfalvi A, Han ZC. 1994. Angiogenic factors are hematopoietic growth factors and vice versa. Leukemia 8:523529.
  • Bonnet D, Dick JE. 1997. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730737.
  • Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R, Dohner H, Pollack JR. 2004. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350:16051616.
  • Dickson GJ, Kwasniewska A, Mills KI, Lappin TR, Thompson A. 2009. Hoxa6 potentiates short-term hemopoietic cell proliferation and extended self-renewal. Exp Hematol 37:322333 e323.
  • Dickson GJ, Liberante FG, Kettyle LM, K OH, Finnegan DP, Bullinger L, Geerts D, McMullin MF, Lappin TR, Mills KI, Thompson A. 2013. HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy. Haematologica 98:121625.
  • Duboule D, Dolle P. 1989. The structural and functional organization of the murine HOX gene family resembles that of Drosophila homeotic genes. Embo J 8:14971505.
  • Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. 2009. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15:22072214.
  • Errico MC, Felicetti F, Bottero L, Mattia G, Boe A, Felli N, Petrini M, Bellenghi M, Pandha HS, Calvaruso M, Tripodo C, Colombo MP, Morgan R, Care A. 2013. The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway. Int J Cancer.
  • Felli N, Cianetti L, Pelosi E, Care A, Liu CG, Calin GA, Rossi S, Peschle C, Marziali G, Giuliani A. 2010. Hematopoietic differentiation: a coordinated dynamical process towards attractor stable states. BMC Syst Biol 4:85.
  • Gohda E, Nakamura S, Yamamoto I, Minowada J. 1995. Hepatocyte growth factor--pleiotropic cytokine produced by human leukemia cells. Leuk Lymphoma 19:197205.
  • Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. 1999. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531537.
  • Grubach L, Juhl-Christensen C, Rethmeier A, Olesen LH, Aggerholm A, Hokland P, Ostergaard M. 2008. Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia. Eur J Haematol 81:112122.
  • He Y, Jiang X, Chen J. 2013. The role of miR-150 in normal and malignant hematopoiesis. Oncogene doi: 10.1038/onc.2013.346. Epub ahead of print.
  • Hope KJ, Jin L, Dick JE. 2004. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 5:738743.
  • Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, Furnari FB, White FM. 2007. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A 104:1286712872.
  • Kenessey I, Keszthelyi M, Kramer Z, Berta J, Adam A, Dobos J, Mildner M, Flachner B, Cseh S, Barna G, Szokol B, Orfi L, Keri G, Dome B, Klepetko W, Timar J, Tovari J. 2010. Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma. Curr Cancer Drug Targets 10:332342.
  • Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Vande Woude G, Licht JD, Kung AL, Staudt LM, Look AT. 2012. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med 18:11181122.
  • Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. 1994. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645648.
  • Lawrence HJ, Rozenfeld S, Cruz C, Matsukuma K, Kwong A, Komuves L, Buchberg AM, Largman C. 1999. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias. Leukemia 13:19931999.
  • Lebert-Ghali CE, Fournier M, Dickson GJ, Thompson A, Sauvageau G, Bijl JJ. 2010. HoxA cluster is haploinsufficient for activity of hematopoietic stem and progenitor cells. Exp Hematol 38:10741086 e1071-1075.
  • Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S, Radmacher MD, Maharry K, Elkahloun A, Yang X, He C, He M, Zhang Z, Dohner K, Neilly MB, Price C, Lussier YA, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Bullinger L, Valk PJ, Delwel R, Lowenberg B, Liu PP, Marcucci G, Bloomfield CD, Rowley JD, Chen J. 2012. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood 119:231424.
  • Liu Y, Zheng W, Song Y, Ma W, Yin H. 2013. Low expression of miR-196b enhances the expression of BCR-ABL1 and HOXA9 oncogenes in chronic myeloid leukemogenesis. PLoS One 8:e68442.
  • Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R. 2005. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65:14791488.
  • Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. 2007. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer 97:368377.
  • Martelli MP, Sportoletti P, Tiacci E, Martelli MF, Falini B. 2013 Mutational landscape of AML with normal cytogenetics: biological and clinical implications. Blood Rev 27:1322.
  • Morgado E, Albouhair S, Lavau C. 2007. Flt3 is dispensable to the Hoxa9/Meis1 leukemogenic cooperation. Blood 109:40204022.
  • Nakamura T, Largaespada DA, Shaughnessy JD, Jr., Jenkins NA, Copeland NG. 1996. Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. Nat Genet 12:149153.
  • Narducci MG, Arcelli D, Picchio MC, Lazzeri C, Pagani E, Sampogna F, Scala E, Fadda P, Cristofoletti C, Facchiano A, Frontani M, Monopoli A, Ferracin M, Negrini M, Lombardo GA, Caprini E, Russo G. 2011. MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sezary syndrome. Cell Death Dis 2:e151.
  • Orkin SH, Zon LI. 2008. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 132:631644.
  • Peruzzi B, Bottaro DP. 2006. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12:36573660.
  • Pick M, Azzola L, Mossman A, Stanley EG, Elefanty AG. 2007. Differentiation of human embryonic stem cells in serum-free medium reveals distinct roles for bone morphogenetic protein 4, vascular endothelial growth factor, stem cell factor, and fibroblast growth factor 2 in hematopoiesis. Stem Cells 25:22062214.
  • Pineault N, Helgason CD, Lawrence HJ, Humphries RK. 2002. Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny. Exp Hematol 30:4957.
  • Ramsey JM, Kettyle LM, Sharpe DJ, Mulgrew NM, Dickson GJ, Bijl JJ, Austin P, Mayotte N, Cellot S, Lappin TR, Zhang SD, Mills KI, Krosl J, Sauvageau G, Thompson A. 2013. Entinostat Prevents Leukemia Maintenance in a Collaborating Oncogene-Dependent Model of CN-AML. Stem Cells. 31:143445
  • Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. 2013. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 121:46554662.
  • Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. 2010. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 28:18561862.
  • Reya T, Morrison SJ, Clarke MF, Weissman IL. 2001. Stem cells, cancer, and cancer stem cells. Nature 414:105111.
  • Robb L. 2007. Cytokine receptors and hematopoietic differentiation. Oncogene 26:67156723.
  • Rozovskaia T, Feinstein E, Mor O, Foa R, Blechman J, Nakamura T, Croce CM, Cimino G, Canaani E. 2001. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality. Oncogene 20:874878.
  • Thompson A, Quinn MF, Grimwade D, O'Neill CM, Ahmed MR, Grimes S, McMullin MF, Cotter F, Lappin TR. 2003. Global down-regulation of HOX gene expression in PML-RARalpha + acute promyelocytic leukemia identified by small-array real-time PCR. Blood 101:15581565.
  • Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ, Humphries K, Sauvageau G. 2002. Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood 99:121129.
  • Tschopp P, Tarchini B, Spitz F, Zakany J, Duboule D. 2009. Uncoupling time and space in the collinear regulation of Hox genes. PLoS Genet 5:e1000398.
  • Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J. 2010. The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol 84:116.
  • Wilhelm BT, Briau M, Austin P, Faubert A, Boucher G, Chagnon P, Hope K, Girard S, Mayotte N, Landry JR, Hebert J, Sauvageau G. 2011. RNA-seq analysis of 2 closely related leukemia clones that differ in their self-renewal capacity. Blood 117:e2738.
  • Wilson A, Murphy MJ, Oskarsson T, Kaloulis K, Bettess MD, Oser GM, Pasche AC, Knabenhans C, Macdonald HR, Trumpp A. 2004. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev 18:27472763.
  • Yekta S, Tabin CJ, Bartel DP. 2008. MicroRNAs in the Hox network: an apparent link to posterior prevalence. Nat Rev Genet 9:789796.
  • Zangenberg M, Grubach L, Aggerholm A, Silkjaer T, Juhl-Christensen C, Nyvold CG, Kjeldsen E, Ommen HB, Hokland P. 2009. The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML. Eur J Haematol 83:439448.